Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2020

Feb 16, 2021

SELL
$96.85 - $148.25 $221 Million - $339 Million
-2,284,744 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$122.47 - $213.56 $5.79 Million - $10.1 Million
47,293 Added 2.11%
2,284,744 $324 Million
Q2 2020

Aug 11, 2020

BUY
$185.52 - $231.25 $1.34 Million - $1.66 Million
7,198 Added 0.32%
2,237,451 $441 Million
Q1 2020

May 14, 2020

SELL
$143.0 - $274.03 $59.1 Million - $113 Million
-413,555 Reduced 15.64%
2,230,253 $437 Million
Q4 2019

Feb 13, 2020

SELL
$146.12 - $215.82 $16.2 Million - $23.9 Million
-110,752 Reduced 4.02%
2,643,808 $547 Million
Q3 2019

Nov 14, 2019

SELL
$130.44 - $187.64 $7.66 Million - $11 Million
-58,749 Reduced 2.09%
2,754,560 $421 Million
Q2 2019

Aug 14, 2019

SELL
$111.45 - $128.93 $7.68 Million - $8.89 Million
-68,951 Reduced 2.39%
2,813,309 $363 Million
Q1 2019

May 15, 2019

SELL
$89.61 - $117.78 $1.1 Million - $1.45 Million
-12,275 Reduced 0.42%
2,882,260 $339 Million
Q4 2018

Feb 14, 2019

SELL
$87.81 - $110.65 $9.2 Million - $11.6 Million
-104,804 Reduced 3.49%
2,894,535 $266 Million
Q3 2018

Nov 14, 2018

BUY
$90.63 - $120.22 $105 Million - $139 Million
1,155,853 Added 62.7%
2,999,339 $337 Million
Q2 2018

Aug 14, 2018

SELL
$88.4 - $105.34 $3.11 Million - $3.71 Million
-35,200 Reduced 1.87%
1,843,486 $170 Million
Q1 2018

May 15, 2018

SELL
$94.51 - $120.23 $11.3 Million - $14.4 Million
-119,625 Reduced 5.99%
1,878,686 $187 Million
Q4 2017

Feb 14, 2018

SELL
$84.48 - $104.02 $3.19 Million - $3.92 Million
-37,705 Reduced 1.85%
1,998,311 $187 Million
Q3 2017

Nov 14, 2017

SELL
$73.17 - $103.47 $7.5 Million - $10.6 Million
-102,475 Reduced 4.79%
2,036,016 $207 Million
Q2 2017

Aug 14, 2017

BUY
N/A
2,138,491
2,138,491 $164 Million

Others Institutions Holding GLPG

About GALAPAGOS NV


  • Ticker GLPG
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 65,835,500
  • Market Cap $1.76B
  • Description
  • Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative coliti...
More about GLPG
Track This Portfolio

Track Sands Capital Management, LLC Portfolio

Follow Sands Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sands Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sands Capital Management, LLC with notifications on news.